RxDoctor Payments Data

Alyssa Coughennower

Psychiatric/Mental Health · West Des Moines, IANPI 1346960978

Payments from drug & device makers

$1,938in general payments, 2019–2025

Across 78 payments — averaging $24.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$335
  • Johnson & Johnson$331
  • AbbVie$215
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$212
  • Corium, LLC$187
  • Otsuka America Pharmaceutical, Inc.$140
  • plus $517 from 13 others

What the payments were for

  • Food & beverage$1,84295%
  • Education$965%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,938 in reported general payments places this provider in the 65th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$11,475
Medicare patients
14
Services billed
185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl19$46,437
VraylarCariprazine Hcl16$24,028
Duloxetine Hcl32$866
Prazosin Hcl22$497
Hydroxyzine Hcl13$257
Alprazolam ErAlprazolam13$226
Lamotrigine29$207
Buspirone Hcl22$194
Clonazepam22$148
Fluoxetine Hcl17$65
Trazodone Hcl12$63
Sertraline Hcl18$42
Lorazepam20$12

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$331$46,43719 claims
AbbVieVraylar$215$24,02816 claims
Almatica Pharma LLCSertraline Hcl$21$4218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in West Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →